Liam Condon, Managing Director of Bayer Healthcare China discusses the  government’s recent announcements regarding its much-anticipated healthcare reform plan, the future benefits of investing in rural…
In Conversation
In the last decade the medical device sector has undergone a lot of change; China has become a net importer to a net exporter of these…
Your business is very much relationship based here in China. You’ve now established a number of relationships with institutes, universities and companies, but I can imagine…
Cheng-Ho Tsai, Mackay Memorial Hospital has a unique background and origins. How has this endured through the different stages of the pharmaceutical sector in Taiwan, and…
You have very successfully executed a vision that you have had for the company since it was a 200 Rs Cr turnover, India-focused enterprise 15 years…
Academia Sinica celebrated its 80th anniversary in 2008. After this milestone, how does the institute define its activities today? Academia Sinica was founded more than eighty…
When Astellas announced to expand its presence in India in 2009, you were already speaking of the company’s long commitment and solid relationship with India. Can…
Dr Ammelburg, you have been working for Roche for more than 25 years now, time essentially spent between your home country Germany and Thailand. After more…
Please introduce Nucleus Network and the role it plays in the Australian pharmaceutical sector. Nucleus Network is an early-phase clinical research business, and is somewhat unique,…
You are General Manager for Thailand and Vietnam; two markets that certainly interest companies but at a very different stage of development. What are according to…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well…
